получавших лечение. При этом наблюдается значительно меньшая частота развития побочных эффекModern therapeutic modes of treatment of autoimmune hepatitis

The aim of review. To present the standard and alternative therapeutic modes used at treatment of autoimmune hepatitis (AIH).Original positions. Autoimmune hepatitis is a chronic inflammatory disease of the liver of the unknown etiology, accompanied by elevation of serum transaminase level, hypergam...

Full description

Saved in:
Bibliographic Details
Main Authors: V. T. Ivashkin, M. A. Morozova, M. V. Mayevskaya, A. O. Buyeverov
Format: Article
Language:Russian
Published: Gastro LLC 2009-08-01
Series:Российский журнал гастроэнтерологии, гепатологии, колопроктологии
Subjects:
Online Access:https://www.gastro-j.ru/jour/article/view/1634
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849234410728062976
author V. T. Ivashkin
M. A. Morozova
M. V. Mayevskaya
A. O. Buyeverov
author_facet V. T. Ivashkin
M. A. Morozova
M. V. Mayevskaya
A. O. Buyeverov
author_sort V. T. Ivashkin
collection DOAJ
description The aim of review. To present the standard and alternative therapeutic modes used at treatment of autoimmune hepatitis (AIH).Original positions. Autoimmune hepatitis is a chronic inflammatory disease of the liver of the unknown etiology, accompanied by elevation of serum transaminase level, hypergammaglobulinemia and circulation of the fixed spectrum of autoantibodies in the blood. In most of the cases disease can be treated by combination of prednisolon and azathioprin. However, according to current data, 20% of the patients remain resistant to these agents or have low tolerability, 10 % have to discontinue treatment due to development of serious side effects. Budesonide is a synthetic glucocorticosteroid which is characterized by rapid metabolism in the liver, having no systemic action. Results of some studies on efficacy and safety of application of budesonide at patients with AIH at various stages of disease are published in the world literature. In the review the data on epidemiology, clinical, diagnostics and main therapeutic strategy at autoimmune hepatitis are covered.Conclusion. Now the combination of prednisolon and azathioprin serves as the classical mode for AIH treatment. Results of original studies demonstrated, that budesonide can be a drug of the 1-st line in patients who received no previous treatment. So, considerably less frequency of side effects development, than at intake of prednisolon and azathioprin combination is observed. However application of budesonide for treatment of liver cirrhosis patients is related to quite high risk of development steroid-related side effects and lower frequency of remission induction.
format Article
id doaj-art-b2d025cfae7c4fcb91cb7424cb09d827
institution Kabale University
issn 1382-4376
2658-6673
language Russian
publishDate 2009-08-01
publisher Gastro LLC
record_format Article
series Российский журнал гастроэнтерологии, гепатологии, колопроктологии
spelling doaj-art-b2d025cfae7c4fcb91cb7424cb09d8272025-08-20T04:03:11ZrusGastro LLCРоссийский журнал гастроэнтерологии, гепатологии, колопроктологии1382-43762658-66732009-08-011944121132получавших лечение. При этом наблюдается значительно меньшая частота развития побочных эффекModern therapeutic modes of treatment of autoimmune hepatitisV. T. Ivashkin0M. A. Morozova1M. V. Mayevskaya2A. O. Buyeverov3Московская медицинская академия им. И.М. СеченоваМосковская медицинская академия им. И.М. СеченоваМосковская медицинская академия им. И.М. СеченоваМосковская медицинская академия им. И.М. СеченоваThe aim of review. To present the standard and alternative therapeutic modes used at treatment of autoimmune hepatitis (AIH).Original positions. Autoimmune hepatitis is a chronic inflammatory disease of the liver of the unknown etiology, accompanied by elevation of serum transaminase level, hypergammaglobulinemia and circulation of the fixed spectrum of autoantibodies in the blood. In most of the cases disease can be treated by combination of prednisolon and azathioprin. However, according to current data, 20% of the patients remain resistant to these agents or have low tolerability, 10 % have to discontinue treatment due to development of serious side effects. Budesonide is a synthetic glucocorticosteroid which is characterized by rapid metabolism in the liver, having no systemic action. Results of some studies on efficacy and safety of application of budesonide at patients with AIH at various stages of disease are published in the world literature. In the review the data on epidemiology, clinical, diagnostics and main therapeutic strategy at autoimmune hepatitis are covered.Conclusion. Now the combination of prednisolon and azathioprin serves as the classical mode for AIH treatment. Results of original studies demonstrated, that budesonide can be a drug of the 1-st line in patients who received no previous treatment. So, considerably less frequency of side effects development, than at intake of prednisolon and azathioprin combination is observed. However application of budesonide for treatment of liver cirrhosis patients is related to quite high risk of development steroid-related side effects and lower frequency of remission induction.https://www.gastro-j.ru/jour/article/view/1634autoimmune hepatitistreatmentglucocorticosteroidscytotoxic drugsbudesonide
spellingShingle V. T. Ivashkin
M. A. Morozova
M. V. Mayevskaya
A. O. Buyeverov
получавших лечение. При этом наблюдается значительно меньшая частота развития побочных эффекModern therapeutic modes of treatment of autoimmune hepatitis
Российский журнал гастроэнтерологии, гепатологии, колопроктологии
autoimmune hepatitis
treatment
glucocorticosteroids
cytotoxic drugs
budesonide
title получавших лечение. При этом наблюдается значительно меньшая частота развития побочных эффекModern therapeutic modes of treatment of autoimmune hepatitis
title_full получавших лечение. При этом наблюдается значительно меньшая частота развития побочных эффекModern therapeutic modes of treatment of autoimmune hepatitis
title_fullStr получавших лечение. При этом наблюдается значительно меньшая частота развития побочных эффекModern therapeutic modes of treatment of autoimmune hepatitis
title_full_unstemmed получавших лечение. При этом наблюдается значительно меньшая частота развития побочных эффекModern therapeutic modes of treatment of autoimmune hepatitis
title_short получавших лечение. При этом наблюдается значительно меньшая частота развития побочных эффекModern therapeutic modes of treatment of autoimmune hepatitis
title_sort получавших лечение при этом наблюдается значительно меньшая частота развития побочных эффекmodern therapeutic modes of treatment of autoimmune hepatitis
topic autoimmune hepatitis
treatment
glucocorticosteroids
cytotoxic drugs
budesonide
url https://www.gastro-j.ru/jour/article/view/1634
work_keys_str_mv AT vtivashkin polučavšihlečeniepriétomnablûdaetsâznačitelʹnomenʹšaâčastotarazvitiâpobočnyhéffekmoderntherapeuticmodesoftreatmentofautoimmunehepatitis
AT mamorozova polučavšihlečeniepriétomnablûdaetsâznačitelʹnomenʹšaâčastotarazvitiâpobočnyhéffekmoderntherapeuticmodesoftreatmentofautoimmunehepatitis
AT mvmayevskaya polučavšihlečeniepriétomnablûdaetsâznačitelʹnomenʹšaâčastotarazvitiâpobočnyhéffekmoderntherapeuticmodesoftreatmentofautoimmunehepatitis
AT aobuyeverov polučavšihlečeniepriétomnablûdaetsâznačitelʹnomenʹšaâčastotarazvitiâpobočnyhéffekmoderntherapeuticmodesoftreatmentofautoimmunehepatitis